Revenue grew 10.3% year-over-year in Q2 2026, with strong gains in both core segments and improved profitability. The company completed a $1.2B acquisition, raised $287.6M in a private placement, and maintained robust liquidity despite macroeconomic and geopolitical headwinds.Original document: Nov…
Q2 2026 saw double-digit revenue and profit growth, with strong cash flow and margins. The Riverpoint Medical acquisition is expected to accelerate growth and profitability, and full-year guidance was raised to reflect robust momentum and expanded medical market exposure.Original document: Novanta…
Novanta reported second-quarter 2026 results with GAAP revenue of $265.8 million and GAAP diluted EPS of $0.30. Adjusted diluted EPS rose to $0.89 and Adjusted EBITDA increased to $60.7 million. The company said organic revenue grew 9.3% year-over-year and cited the Riverpoint Medical acquisition a…
Medicine and manufacturing technology provider Novanta NASDAQ:NOVT will be reporting earnings this Wednesday after market hours. Here’s what to look for.Novanta beat analysts’ revenue expectations last quarter, reporting revenues of $257.7 million, up 10.4% year on year. It was a satisfactory quart…
